Medtronic (MDT) Announces FDA Approval for Expanded Indication of OmniaSecure

On March 23, 2026, Medtronic plc (NYSE:MDT) received U.S. FDA support for an expanded denotation for its OmniaSecure defibrillation lead, present allowing placement successful the near bundle subdivision country for conduction strategy pacing. The institution said this attack much intimately mimics the heart’s earthy physiology, with further benefits for patients requiring cardiac resynchronization done combined pacing techniques.

On March 10, 2026, Medtronic plc (NYSE:MDT) announced a definitive statement to get Scientia Vascular for $550M, with imaginable further earn-out payments. The institution said the deal, expected to adjacent successful the archetypal fractional of FY27, volition beryllium minimally dilutive to adjusted EPS successful FY27 and accretive thereafter. Scientia operates successful Salt Lake City with astir 310 employees.

al7/Shutterstock.com

Last month, Medtronic plc (NYSE:MDT) reported Q3 EPS of $1.36, supra the $1.34 statement estimate, connected gross of $9.02B versus $8.89B expected. CEO Geoff Martha said the institution delivered “strong” show with 6% integrated gross growth, highlighting continued concern successful innovation and enlargement into caller markets to enactment semipermanent growth.

Medtronic plc (NYSE:MDT) develops and manufactures aesculapian devices and therapies utilized crossed a scope of healthcare applications.

While we admit the imaginable of MDT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.